Are ADCs in lung cancer living up to expectations?
High rates of adverse events in the experimental setting seem to limit the potential of antibody–drug conjugates for patients with NSCLC
High rates of adverse events in the experimental setting seem to limit the potential of antibody–drug conjugates for patients with NSCLC
About 4% of US cancer survivors surveyed said they adhere to the American Cancer Society’s nutrition and physical activity guidelines.
Health Canada has approved subcutaneous atezolizumab for use in patients with lung cancer, breast cancer, and hepatocellular carcinoma.
With ablation, a small needle is inserted to precisely zap a tumor — by freezing or heating it. The treatment is over 90% effective in…
A subgroup of patients from the 3 CARTITUDE trials experienced cranial nerve palsy after treatment, most of whom were men.
After his acute myelomonocytic leukemia treatment failed, Curt Bogard came to MD Anderson for treatment, which included a stem cell transplant. Today, he considers the…
Fred Hutch ovarian cancer researchers Drs. Holly Harris and Elizabeth Swisher each received $200,000 from the Rivkin Center/Andy Hill CARE Fund to identify risk factors…
VCN-01 was safe and elicited signs of antitumor activity in patients with intraocular retinoblastoma that was refractory to chemotherapy or radiotherapy.
Sanjay K. Juneja, MD, Targeted Oncology’s first 2024 Oncology Icon, delves into his background and what drove him to pursue a career in oncology.
A scoping review analyzed the degree to which published phase II to IV trials of combination immune checkpoint inhibitor (ICI) and VEGF inhibitor treatment of…
Background/Significance: Oncology nurses deliver evidence-based clinical care w…